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ed with palliative chemotherapy at Samsung Medical Center, Seoul, 
Korea were retrospectively reviewed. According to a case-match-con-
trol study design, 334 patients matched by age, sex, and histology for 
each treatment period; pre-geﬁtinib era (1999-2001) and post-geﬁtinib 
era (2002-2005) were selected and compared for overall survival. For 
each group, 69.5% were male, 53.3% were < 60 years, and 66.5% of 
patients had adenocarcinoma. 
Results: With the median follow-up of 68 and 30 months in pre- and 
post-geﬁtinib eras, the median overall survival (OS) from the date of 
ﬁrst diagnosis of advanced/metastatic or recurrent disease were 11.5 
(95% CI, 10.0-12.9 months) and 19.3 (95% CI, 17.2-21.3 months) 
months, respectively, which was signiﬁcantly different (p<0.001). The 
overall response rate and disease control rate were 24.7% (3 complete 
response, 73 partial response) and 48.7% for 308 evaluable post-geﬁ-
tinib era patients, respectively. By multivariate analysis for all the 668 
patients, geﬁtinib treatment (HR 0.64, P<0.001), Stage III (HR 0.64, 
P<0.001), PS ≤1 (HR 0.57, P<0.001), adenocarcinoma histology (HR 
0.80, P=0.025), and prior chemotherapy ≤2 (HR 0.66, P<0.001) were 
signiﬁcant favorable predictors for survival . Exploratory subgroup 
analyses also showed a prolonged overall survival for patients in 
post-geﬁtinib era in almost all subgroups: age <60 (12.7 vs 20.6 M, 
P<0.001). age ≥60 (10.6 vs 18.1 M, P<0.001), male (11.4 vs 16.5 M, 
P<0.001), female (12.4 vs 25.1 M, P<0.001), never-smokers (12.6 vs 
24.9 M, P<0.001), smokers (10.9 vs 15.7 M, P<0.001), stage III (14.2 
vs 24.7 M, P<0.001), stage IVRecurrent (9.9 vs 17.6 M, P<0.001), 
adenocarcinoma histology (12.6 vs 24.2 M, P<0.001), performance 
status (PS) ≤1 (12.7 vs 20.4, P<0.001), prior chemotherapy ≥1 (11.7 vs 
20.0 M, P<0.001), and previous platinum based chemotherapy (11.7 vs 
20.3 M, P<0.001). 
Conclusions: This historical control study shows signiﬁcant improve-
ment of overall survival with the introduction of geﬁtinib in clinic to 
the treatment of advanced/metastatic NSCLC patients. These results 
strongly suggest the efﬁcacy as well as the survival advantage of 
EGFR tyrosine kinase inhibitor in Asian population for the treatment of 
advanced NSCLC. 
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Background: Data suggest that following treatment with erlotinib at 
150 mg/d, current smokers have lower exposure, experience less rash 
and achieve less survival beneﬁt than former or never smokers. It has 
been hypothesized that this may be due, in part, to induction of CYP 
enzymes by tobacco use and that a higher dose of erlotinib, if feasible, 
may improve outcome in current smokers. 
Methods: A 2-part study was initiated to escalate erlotinib to the Maxi-
mum Tolerated Dose (MTD) in current smokers and evaluate pharma-
cokinetics (PK) at this MTD versus 150 mg/d. Part I: sequential cohorts 
of advanced NSCLC patients (pts) that were current smokers received 
escalating doses of erlotinib for 14 days until MTD was deﬁned. Part 
II: pts were randomized between the MTD and 150 mg/d erlotinib and 
PK assessed at D14. 
Results: Twenty-two pts were enrolled in Part I at 4 dose levels; 200, 
250, 300 and 350 mg/d. Dose limiting toxicities were observed in 1/6 
MTD-evaluable pts at 300 mg/d (G3 rash) and 2/5 pts at 350 mg/d (G3 
acneiform dermatitis and G3 fatigue/decreased ECOG PS). Thirteen pts 
have been entered into Part II to date, 7 randomized to 300 mg/d and 
6 to 150 mg/d. Median age is 59 yrs (range 52-74) with 7 males and 
6 females. Histology: Adenocarcinoma (7/13), Squamous (5/13) and 
other (1/13). Median/range number of cigarettes smoked and duration 
of smoking is 15/d (10-25) and 42 yrs (20-63), respectively. Erlotinib 
dose of 300 mg/d has been well tolerated to date, with a single case 
of G3 diarrhea. Other toxicity among all 13 pts has been grade 1 or 2, 
mainly skin toxicity (46%) and diarrhea (31%). Preliminary PK data 
(n=10) show median plasma Cmax of erlotinib was 1.77 (range 0.85-
4.58) versus 3.48 (range 1.14-4.88) ug/mL for 150 and 300 mg/d dose 
cohorts, respectively. The median AUCTau of erlotinib was 29.3 (range 
19.8-50.9) versus 46.2 (range 23.7-95.2) ug.hr/mL for 150 and 300 
mg/d dose cohorts, respectively. PK of the main metabolite of erlotinib, 
OSI-420, mirrored erlotinib PK. The median trough plasma concentra-
tion at steady state (CminSS) of erlotinib was 0.42 and 1.84 ug/mL for 
150 and 300 mg/d dose cohorts, respectively. 
Conclusions: The MTD of erlotinib in NSCLC pts who continue to 
smoke was 300 mg/d. Early data indicate that there is a dose-dependent 
increase in the systemic erlotinib exposure in current smokers. Enroll-
ment in to Part II continues and updated data will be presented.
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Erlotinib was approved for funding as a systemic therapy treatment for 
third line management of advanced NSCLC by the BC Cancer Agency 
(BCCA) in April 2004. BCCA patient outcome and cost data are 
routinely collected to verify the therapeutic effectiveness and cost-ef-
fectiveness of systemic treatment policies.
This was a pragmatic retrospective analysis of all patients who received 
third line erlotinib compared to a historical group treated with second 
line docetaxel then no further active treatment, both according to BCCA 
protocol. The primary end-point was cost-effectiveness, measured in 
terms of cost-per-life-year-gained. Secondary end-points included: 
median overall survival (MOS); overall survival (OS) at one year; and 
comparison to phase III efﬁcacy results. Data was retrieved from the 
Cancer Agency Information System (CAIS) and Systemic Therapy Data 
Warehouse. Life-years-gained were calculated from the area under the 
survival function curve. CEA took the BCCA perspective and costs 
included all direct drug costs for treatment of advanced disease. Sensi-
tivity analyses included varying life expectancy across its 95% CI, cost 
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to the extremes of ranges, and start date for length of survival: method 
1. progression after second line therapy or three weeks post last dose of 
chemo for control group and start date of erlotinib for treatment group; 
method 2. last date of second line therapy for both groups. 
75 control and 70 erlotinib patients were included in the analysis. 
Results are presented in the table. The Incremental Cost-Effectiveness 
Ratio (ICER) was $28,516 per life-year-gained under method 1, and 
$17,632 under method 2. The erlotinib group had similar one year OS 
compared to literature (36 vs. 31%).
Method 1: Parameter Controls (N=75) Erlotinib (N=70)
Area under curve (months) 3.86 7.91
p-value (log-rank test) <0.001
Median Survival months (95% CI) 2.56 (2.04-4.8) 4.73 (2.89-14.7)
1-year OS % (95% CI) 0.04 (0.01-0.13) 0.36 (0.24-0.53)
Mean drug cost $CDN/patient (range) 7,560 (1,445-26,710) 17,184 (2,660-58,539)
ICER $28,516/LYG
Method 2: Parameter
Area under curve 5.35 11.90
p-value (log-rank test) <0.001
Median Survival months (95% CI) 3.35 (2.53-6.38) 8.61 (7.56-19.99)
1-year OS % (95% CI) 0.11 (0.06-0.21) 0.45 (0.34-0.60)
ICER $17,632/LYG
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Background: Epidermal Growth Factor Receptor tyrosine kinase 
Inhibitors (EGFRTKI) have proven selective efﬁcacy in advanced 
NSCLC where potential predictors of response have been studied. 
Their role in early stage NSCLC has not been established.
Purpose: Using pharmacodynamic sampling pre- and post-therapy 
with geﬁtinib, 1) to assess the impact of geﬁtinib on EGFR intracellular 
signaling pathways; and 2) to assess response and toxicity rates after 
preoperative geﬁtinib (Iressa, AstraZeneca)
Methods: Stage I NSCLC patients received geﬁtinib (Iressa, 250 
mg/day) for 28 days followed by mediastinoscopy and surgical resec-
tion in a single arm open label study. Tumor response was evaluated by 
RECIST. Pre-treatment (snap frozen, core needle biopsy) and post-
operative (snap frozen and formalin ﬁxed, surgical specimen) tumor 
samples were obtained. Mutation analysis of EGFR exons 19 and 21 
was performed by PCR fragment length analysis and direct sequencing. 
EGFR, its phospho-isoforms and intracellular signaling pathways were 
analyzed by immunohistochemistry 
Results: Thirty-four patients have completed treatment. Mean fol-
low-up is 4.7 months (2.3-11.6). Sixty-ﬁve percent of cases were 
adenocarcinomas, 21% squamous cell, 12% pure BAC, and 3% large 
cell carcinoma. Fifty percent were active smokers, 38% former smok-
ers and 12% never smoked. No unexpected toxicities during geﬁtinib 
treatment were seen. Five patients had serious adverse events within 
30 days post-surgery (2 pulmonary infections, 2 prolonged air leaks, 1 
pulmonary embolism). Four (12%) patients had exon 19 deletions and 
two (6%) had exon 21 point mutations. Two pts with exon 19 deletions 
had a partial response (PR) to treatment, the others stable disease (SD). 
One pt with exon 21 point mutation had a PR, the other SD. In patients 
without mutation, 1 had a PR, 22 SD, and 3 PD on therapy. The overall 
response rate was 11.7% in the sample. No differences in mutations 
were detected comparing pre- and post-treatment specimens. 
By univariate analyses (Fisher’s Exact Test and t-Test), presence of ﬁ-
brosis in surgically resected specimens was associated with any EGFR 
mutation (p=0.002) and exon 19 deletion alone (p=0.008). Female gen-
der (p=0.007), never-smoking status (0.029), BAC (p=0.009), EGFR 
mutation (p=0.002), and exon 19 deletion (p=0.023) were associated 
with a reduction in maximum tumor diameter, but only any EGFR mu-
tation (p=0.016) was associated with RECIST response. In multivariate 
analysis, the only variable associated with tumor reduction, RECIST re-
sponse and ﬁbrosis was the presence of any EGFR mutation, (p=0.016). 
Preliminary analysis suggests non responders are not experiencing 
complete EGFR inhibition in vivo. Additional measures associated with 
response are under assessment. 
Conclusions: Geﬁtinib can be administered safely preoperatively in 
early NSCLC. EGFR mutation analysis is feasible on percutaneous 
biopsies. Short-term EGFRTKI treatment does not result on changes in 
mutation proﬁle. Comparison of pre- and post-therapy tumor samples 
may allow additional understanding of EGFR TKI resistance and facili-
tate patient selection.
Overall, response rates and predictors of response in early stage 
NSCLC are not different from advanced disease.
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Background: The phase III randomised BR.21 study demonstrated 
that in patients with relapsed advanced NSCLC, erlotinib (Tarceva®) 
improved survival and prolonged time to symptom deterioration 
compared with placebo (Shepherd et al. NEJM 2005;353:123-132). 
Erlotinib was well tolerated, with rash and diarrhoea the most com-
mon adverse events (AEs), both being generally mild to moderate in 
severity. The global, open-label TRUST study was initiated to provide 
erlotinib access to patients with advanced NSCLC. Data are reported 
here for the E/SE subgroup.
Methods: Eligible patients with stage IIIB/IV NSCLC had failed previ-
ous chemotherapy for advanced disease (≤2 prior regimens) or were 
unsuitable for chemotherapy. Erlotinib was administered orally 150mg/
